Weal and woe of interleukin-18 in the T cell therapy of cancer.

Chimeric antigen receptor (CAR) T cell therapy of solid cancer remains below expectations; adding cytokine help through IL-18 has shown remarkable efficacy in first clinical trials. As IL-18 is also a powerful driver of hyperinflammatory conditions, we discuss to what extent unleashing IL-18 is a double-edged sword in CAR T cell therapies. © Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.

Citation

Christoph Kessel, Claudia Rossig, Hinrich Abken. Weal and woe of interleukin-18 in the T cell therapy of cancer. Journal for immunotherapy of cancer. 2025 Jan 14;13(1)

Mesh Tags

Substances

PMID: 39809514

search → result